In the naïve population, we are seeing efficacy of anti-TNF therapies and combination of anti-TNFs with immunomodulators, which reflects current practice and the key recommendations from the most recent British Society of Gastroenterology’s (BSG) IBD guidelines.15 This evidence concerns the gene TNF and inflammatory bowel disease.